Capital Markets

Recapitalization by

December 2023 – England & Company is pleased to announce that it served as the exclusive financial advisor and placement agent in the debt and equity recapitalization of  OneroRx, Inc. (“OneroRx”). The financing, provided by Cyprium Investment Partners LLC (“Cyprium”) and Wells Fargo Bank, allowed OneroRx to realign its shareholder base and strengthen its balance sheet, and will enable it to continue to grow through acquisitions.

OneroRx, based in West Des Moines, IA, is a leading technology-enabled, integrated pharmacy services company operating community pharmacies and telepharmacies in underserved rural and urban areas in six states in the Midwest. In its locations, OneroRx maintains a smaller physical footprint than the national pharmacy chains and more efficient operations that enable the Company to better meet the needs of underserved communities and focus on clinical services rather than retail. The Company’s growth strategy incorporates acquisitions, building de novo sites, growing its patient base, and leveraging additional specialty services across its network.

“We have a robust M&A pipeline, and this transaction gives us the flexibility we need to position ourselves better to invest in growing the business,” said Joseph Dunham, OneroRx’s Chief Executive Officer. Dunham added, “The England team was critical in evaluating our alternatives, finding the right partners, and bringing this transaction together.”

Series C Preferred Stock $38,500,000

October 2022 – England Securities served as the exclusive placement agent to Ossio Ltd. (“Ossio”), a rapidly growing orthopedic fixation technology company, in its $38.5 million Series C financing. This financing, which was led by MVM Partners (“MVM”), a Boston- and London-based growth equity firm, represents England’s 9th transaction in orthopedics, and 5th transaction specifically in foot & ankle orthopedics.

Ossio, based in Woburn, MA and Caesarea, Israel, produces orthopedic implants made with OSSIOfiber® Intelligent Bone Regeneration Technology, a breakthrough in fixation material that provides the first credible solution to the shortcomings of permanent metal hardware, conventional resorbable, and allograft implants. The technology provides for unparalleled mechanical strength and natural bone healing in a non-permanent implant.

“We are delighted to have secured this level of interest and commitment from such an experienced and distinguished medical technology investment firm,” said OSSIO’s Chief Executive Officer, Brian Verrier. “England’s Healthcare Investment Banking team was instrumental in helping us secure an ideal lead investor with relevant orthopedic experience and a focus on companies of our stage.”

“We believe that OSSIO’s novel bio-integrative technology has the potential to transform the orthopedic fixation market,” said MVM’s founding Partner, Dr. Stephen Reeders. “We are excited to support the company’s mission to improve patient outcomes across a broad range of procedures.” Dr. Reeders and his MVM colleague, Dr. Kevin Cheng, join OSSIO’s board of directors as part of this financing.

Verrier continued, “The additional funding will enable us to accelerate further adoption of OSSIOfiber Intelligent Bone Regeneration Technology by orthopedic and podiatric surgeons in the United States. Specifically, we intend to use these funds to fortify new product development, sales force expansion, patient outreach and medical education.”

Made from a proprietary mineral fiber matrix held together by a naturally degradable polymer, the material is biointegrative (replaced by natural bone over time) and provides surgeons with a more biologically friendly way to restore patient stability and mobility while leaving nothing permanent behind. More than 10,000 OSSIOfiber implants have already been used in orthopedic surgeries since their commercial introduction in 2019.